Pevonedistat, a First in-class NEDD8-activating Enzyme Inhibitor, sensitizes cancer cells to VSV∆51 Oncolytic Virotherapy
Published: 2 October 2023| Version 2 | DOI: 10.17632/2fnzs3jpg4.2
Contributor:
Boaz WongDescription
Raw data for all figures of "Pevonedistat, a First in-class NEDD8-activating Enzyme Inhibitor, sensitizes cancer cells to VSV∆51 Oncolytic Virotherapy", published to Molecular Therapy https://www.cell.com/molecular-therapy-family/molecular-therapy/pdf/S1525-0016(23)00504-X.pdf
Files
Institutions
Ottawa Hospital Research Institute, University of Ottawa
Categories
Immunology, Cellular Aspects of Innate Immunity, Oncolytic Virus